

Elrexio and Talvey to require prior authorization for most members starting June 20

For dates of service on or after June 20, 2024, the following drugs will require prior authorization through the Oncology Value Management program:

- ElrexioTM (elranatamab-bcmm), HCPCS J1323
- TalveyTM (talquetamab-tgvs), HCPCS J3055

The Oncology Value Management program is administered by Carelon Medical Benefits Management. These drugs are part of members' medical benefits, not their pharmacy benefits.

Prior authorization requirements apply when these drugs are administered in outpatient settings for:

- Blue Cross Blue Shield of Michigan commercial —
 - All fully insured members (group and individual)
 - Members who have coverage through [self-funded groups that have opted in to the Oncology Value Management program](#). (Although UAW Retiree Medical Benefits Trust non-Medicare plans have opted into this program, these requirements may not apply; refer to their medical oncology drug list, which is linked below.)

Note: This requirement doesn't apply to members who have coverage through the Blue Cross and Blue Shield Federal Employee Program[®].

- Medicare Plus Blue members
- Blue Care Network commercial members
- BCN Advantage members

How to submit prior authorization requests

Submit prior authorization requests to Carelon using one of the following methods:

- Through the Carelon ProviderPortal, which you can access by doing one of the following:
 - Logging in to our provider portal ([availity.com](#)*), clicking *Payer Spaces* and then clicking the BCBSM and BCN logo. This takes you to the Blue Cross and BCN payer space, where you'll click the *Carelon ProviderPortal* tile.

Note: If you need to request access to our provider portal, see the [Register for web tools](#) webpage on [bcbsm.com](#).

- Logging in directly to the Carelon ProviderPortal at [providerportal.com](#)*.

- By calling the Carelon Contact Center at 1-844-377-1278

Drug lists

For additional information on requirements related to drugs covered under the medical benefit, refer to the following drug lists:

- Blue Cross commercial and BCN commercial:
 - [Oncology Value Management program prior authorization list for Blue Cross and BCN commercial members](#)
 - [Blue Cross and BCN utilization management medical drug list](#)
- URMBT members with Blue Cross non-Medicare plans:
 - [Oncology Value Management program prior authorization list for UAW Retiree Medical Benefits Trust PPO non-Medicare members](#)
 - [Medical Drug Management with Blue Cross for UAW Retiree Medical Benefits Trust PPO non-Medicare Members](#)
- Medicare Plus Blue and BCN Advantage members:
 - [Medical Drug and Step Therapy Prior Authorization List for Medicare Plus Blue and BCN Advantage members](#)

We'll update the pertinent drug lists to reflect the information in this message prior to the effective date.

As a reminder, prior authorization isn't a guarantee of payment. Health care practitioners need to verify eligibility and benefits for members.

[Subscribe](#) to Provider Alerts Weekly, a weekly email with a list of links to the previous week's provider alerts.

*Clicking this link means that you're leaving the Blue Cross Blue Shield of Michigan and Blue Care Network website. While we recommend this site, we're not responsible for its content.

Carelon Medical Benefits Management is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to manage prior authorizations for select services.